Synthetic peptide, and cosmetic composition or pharmaceutical composition and application thereof
US-2024352069-A1 · Oct 24, 2024 · US
MHC-I restricted epitopes containing non-natural amino acid residues
US9109007B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9109007-B2 |
| Application number | US-201113817261-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 18, 2011 |
| Priority date | Aug 18, 2010 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. The exemplary polypeptides are derived from the survivin, hTERT, CYP1B1 and MART-1 antigens.
First claim
Opening claim text (preview).
The invention claimed is: 1. A peptide derivative having the general formula A-X aa -GIGILTV (SEQ ID NO:3), wherein X aa is a non-natural amino acid that provides increased conformational constraint in the peptide derivative compared to the conformational constraint present in the parent peptide having amino acid sequence AAGIGILTV (SEQ ID NO:1), wherein X aa is selected from the group consisting of [c3a], [c5g], [chg], [cpg], [dfb], [dhl], [phg], and [sta]. 2…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Physics · mapped topic
Physics · mapped topic
Physics · mapped topic
- C07K7/06Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9109007B2 cover?
- The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place o…
- Who is the assignee on this patent?
- Kyle Donald J, Soltis Daniel A, Tussey Lynda G, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K7/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).